| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| A1013-PE | Anti-human CLDN 18.2 mAb, E9-PE | 100µl | $350 | Order |
| Catalog Number | A1013-PE |
|---|---|
| Product Name | Anti-human CLDN 18.2 mAb, E9-PE |
| Clone | E9 |
| Isotype | Human IgG1 |
| Formulation | Sterile PBS, pH 6.8, 0.1% NaN3 |
| Stability & Storage | At least 30 days at 4oC; at least 6 months at <-20oC |
| Application | Flow cytometry analysis |
| Product Datasheet: | Download PDF |
Detection of human CLDN18.2 expression on human CLDN18.2-CHO-K1 cells (Cat. #C3011) using recombinant anti-huCLDN18.2 mAbsE9-PE (Cat. #A1013-PE).
Claudin-18 (CLDN18) is a member of a large family of four-span transmembrane proteins called Claudins. These proteins are the essential components of the mammalian tight junctions (TJs) in epithelial cells. Claudin-18 has two splice variants, 18.1 and 18.2. While CLDN18.1 is specifically expressed in the lung tissue, CLDN18.2 expression in normal tissue is more restricted and is only detected in small patches of stomach mucosal. CLDN18.2 expression is elevated in many types of epithelial cancers including stomach, esophagus, pancreatic and ovarian cancers. The expression of CLDN18.2 is not only detected in primary tumors, but also in the metastatic sites. Therefore, CLDN18.2 is an ideal target for monoclonal antibody-based cancer therapies.